
    
      This is a single-center, open-label, Phase I study of single-agent GMX1777 administered every
      3 weeks to patients with CLL, MM, refractory solid tumors or lymphomas. No investigational or
      commercial agents or therapies other than those described may be administered with the intent
      to treat the patient's malignancy.
    
  